Aimmune Therapeutics (AIMT)

[crudeoil24]

RBC Capital Maintains Outperform, Notes 3 Reasons Why The Palforzi Label Is The Best-Case Label Along With Potential Commercial Tailwinds:
9:57 am ET February 3, 2020 (Benzinga) Print
1) an indication for “confirmed diagnosis of peanut allergy” in pediatrics and adolescents that is NOT dependent on undergoing an oral food challenge

2) a monitoring period of “1-hour post-dosing” during dose escalation, which we see as largely in line with monitoring requirements for routine allergy shots

3) label details that do not restrict maintenance and continued updosing to childhood and enable continuation through adulthood

Latest Ratings for AIMT DateFirmActionFromTo

Feb 2020MaintainsMarket Outperform Feb 2020MaintainsOverweight Dec 2019Initiates Coverage OnNeutral